PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31646806-10	2019	The VEGF and MMP-2 levels in both DTX+DDP and TAX+DDP group were decreased compared with those before treatment (183.35+-25.26 vs. 279.18+-27.75 pg/mL and 228.22+-40.21 vs. 316.11+-33.6 pg/mL (p<0.05).	2-dimethylaminoethyl(dimethylamido)phosphonofluoridate	38-41	matrix metallopeptidase 2	Homo sapiens	13-18	
31646806-10	2019	The VEGF and MMP-2 levels in both DTX+DDP and TAX+DDP group were decreased compared with those before treatment (183.35+-25.26 vs. 279.18+-27.75 pg/mL and 228.22+-40.21 vs. 316.11+-33.6 pg/mL (p<0.05).	2-dimethylaminoethyl(dimethylamido)phosphonofluoridate	50-53	matrix metallopeptidase 2	Homo sapiens	13-18	
31646806-14	2019	However, DTX+DDP is more efficacious in lowering indicators such as serum CA125, HE4 and MMP-2 and ROMA index and adverse reactions, thus providing a more efficient practice scheme with lower toxic side effects for the clinical treatment of ovarian carcinoma.	2-dimethylaminoethyl(dimethylamido)phosphonofluoridate	13-16	matrix metallopeptidase 2	Homo sapiens	89-94